Last Updated: 17/03/2025
Innovations in Malaria Vaccine Development (IMV)
Objectives
The main aim of this study is to Identify and advance a malaria vaccine that improves on RTS,S by:
- Increasing benefit to at-risk populations by improving efficacy and/or durability of protection
- Facilitating access to populations most in need by decreasing number of doses and/or by reducing cost.
Core Scientific Strategy:
- Design and develop vaccine candidates that reduce both the rate of infection and blood stage replication.
- Use mechanistic understanding to guide design of candidates
Targets:
- Preclinical data indicates >2 years of high-level protection against disease
- Projected cost of goods <$3 per dose2-3 administrations in primary series, with potential to boost efficacy after
- 2-3 years
Despite impressive declines in malaria deaths and cases over the past two decades, progress has stalled, and malaria continues to kill over 400,000 people each year; young African children remain most vulnerable. New tools are urgently needed to reduce disease and death attributable to malaria, and to accelerate elimination and eventual eradication. PATH is working hard to develop innovative approaches to reduce morbidity and mortality. A highly effective malaria vaccine would be a powerful tool against the disease. This impactful collaboration with USAID could develop a potentially life-saving tool in the fight against malaria, and PATH looks forward to advancing this initiative.
Article: Characterizing the Plasma IgG Antibody Repertoire of Malaria-Naïve United Kingdom Adults Vaccinated with Novel Blood Stage Vaccine RH5.1/AS01 BArticle: Rational structure-guided design of a blood stage malaria vaccine immunogen presenting a single epitope from PfRH5
Jun 2020 — Jun 2026
$27.3M
Related Resources
